Yifan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yifan Wang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Fengyun Wang
Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese, Medical Sciences, China
3 shared publications - Xudong Tang
Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
3 shared publications - Jiaqi Zhang
Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
2 shared publications - Jing Ma
Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
2 shared publications - Jinke Huang
Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China
2 shared publications Beihua Zhang
Department of Gastroenterology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, China; Institute of Digestive Diseases, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, China
1 shared publication
Latest Publications
- Open Access
- 16 January 2025
- Published by Wiley in Mediators of Inflammation
- Vol. 2025 (1) , 7468297
Modified Gegen Qinlian Decoction Ameliorates DSS‐Induced Colitis in Mice via the Modulation of NF‐ κ B and Nrf2/HO‐1 Pathways
Background: This study aims to reveal the potential molecular mechanisms of modified Gegen Qinlian decoction (MGQD) in relieving ulcerative colitis (UC). Methods: C57BL/6J mice were used to establish experimental colitis via dextran sodium sulfate (DSS). Body weight, disease activity index (DAI), spleen weight, colon length, and histopathologic features were measured to evaluate the therapeutic effects of MGQD on mice with UC. The ELISA kits were employed to assess the concentrations of interleukin (IL)‐6, IL‐1β, tumor necrosis factor‐α (TNF‐α), glutathione (GSH), reactive oxygen species (ROS), and malondialdehyde (MDA). Western blot analyses were used to assess the levels of IκBα, p65, p‐IκBα, p‐p65, HO‐1, and Nrf2. Moreover, the protein levels of Nrf2 and p‐p65 were assessed by immunofluorescence. Results: Colitis‐related symptoms in mice were significantly alleviated by MGQD. Moreover, MGQD inhibited the levels of TNF‐α, IL‐1β, IL‐6, MDA, and ROS and increased the level of GSH in mice with UC. Mechanistically, MGQD prevented the activation of the NF‐κB pathway and concomitantly promoted the activation of the Nrf2/HO‐1 pathway. Conclusion: MGQD alleviated UC by suppressing inflammation and oxidative stress via the modulation of NF‐κB and Nrf2/HO‐1 pathways, suggesting that MGQD may be a candidate therapy for UC.
- 16 January 2025
- Published by Wiley in Mediators of Inflammation
- Vol. 2025 (1) , 7468297
Open AccessModified Gegen Qinlian Decoction Ameliorates DSS‐Induced Colitis in Mice via the Modulation of NF‐ κ B and Nrf2/HO‐1 Pathways
Background: This study aims to reveal the potential molecular mechanisms of modified Gegen Qinlian decoction (MGQD) in relieving ulcerative colitis (UC). Methods: C57BL/6J mice were used to establish experimental colitis via dextran sodium sulfate (DSS). Body weight, disease activity index (DAI), spleen weight, colon length, and histopathologic features were measured to evaluate the therapeutic effects of MGQD on mice with UC. The ELISA kits were employed to assess the concentrations of interleukin (IL)‐6, IL‐1β, tumor necrosis factor‐α (TNF‐α), glutathione (GSH), reactive oxygen species (ROS), and malondialdehyde (MDA). Western blot analyses were used to assess the levels of IκBα, p65, p‐IκBα, p‐p65, HO‐1, and Nrf2. Moreover, the protein levels of Nrf2 and p‐p65 were assessed by immunofluorescence. Results: Colitis‐related symptoms in mice were significantly alleviated by MGQD. Moreover, MGQD inhibited the levels of TNF‐α, IL‐1β, IL‐6, MDA, and ROS and increased the level of GSH in mice with UC. Mechanistically, MGQD prevented the activation of the NF‐κB pathway and concomitantly promoted the activation of the Nrf2/HO‐1 pathway. Conclusion: MGQD alleviated UC by suppressing inflammation and oxidative stress via the modulation of NF‐κB and Nrf2/HO‐1 pathways, suggesting that MGQD may be a candidate therapy for UC.
- Open Access
- 14 March 2022
- Published by Wiley in Gastroenterology Research and Practice
- Vol. 2022, 1-8
Scientific Evidence of Chinese Herbal Medicine (Gegen Qinlian Decoction) in the Treatment of Ulcerative Colitis
Objectives. Gegen Qinlian decoction (GQD), a Chinese herbal compound, has been widely used in the treatment of ulcerative colitis (UC) in China. However, evidence from systematic reviews (SRs)/meta-analyses (MAs) of GQD in UC remains highly controversial. To collate, evaluate, and synthesize the current evidence, we carried out this study. Methods. SRs/MAs of GQD for UC were obtained from eight databases. Methodological Quality of Systematic Reviews 2 (AMSTAR-2) was utilized to appraise the methodological quality, Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA) for reporting quality, and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) for evidence quality. Results. Four eligible SRs/MAs were obtained. According to AMSTAR 2, all SRs/MAs were graded as critically low quality. According to PRISMA checklist, all SRs/MAs failed to report the information of protocol and registration. With GRADE, no outcome measure with high-quality evidence was found, and the evidence quality for outcome measures was in the moderate to critically low levels. Conclusions. GQD with conventional medicine (CM) seems to be more effective in UC than CM alone. This finding provides a new alternative strategy for the treatment of UC. However, owing to the limitations of the evidence provided by the included SRs/MAs, this conclusion must be treated with caution.
- 14 March 2022
- Published by Wiley in Gastroenterology Research and Practice
- Vol. 2022, 1-8
Open AccessScientific Evidence of Chinese Herbal Medicine (Gegen Qinlian Decoction) in the Treatment of Ulcerative Colitis
Objectives. Gegen Qinlian decoction (GQD), a Chinese herbal compound, has been widely used in the treatment of ulcerative colitis (UC) in China. However, evidence from systematic reviews (SRs)/meta-analyses (MAs) of GQD in UC remains highly controversial. To collate, evaluate, and synthesize the current evidence, we carried out this study. Methods. SRs/MAs of GQD for UC were obtained from eight databases. Methodological Quality of Systematic Reviews 2 (AMSTAR-2) was utilized to appraise the methodological quality, Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA) for reporting quality, and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) for evidence quality. Results. Four eligible SRs/MAs were obtained. According to AMSTAR 2, all SRs/MAs were graded as critically low quality. According to PRISMA checklist, all SRs/MAs failed to report the information of protocol and registration. With GRADE, no outcome measure with high-quality evidence was found, and the evidence quality for outcome measures was in the moderate to critically low levels. Conclusions. GQD with conventional medicine (CM) seems to be more effective in UC than CM alone. This finding provides a new alternative strategy for the treatment of UC. However, owing to the limitations of the evidence provided by the included SRs/MAs, this conclusion must be treated with caution.